Janssen
J&J to supply 500,000 Ebola vaccines to fight DR Congo outbreak
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing Ebola, Janssen, Johnson & Johnson, pharma
Johnson & Johnson has reached an agreement with the Government of the Democratic Republic of the Congo (DRC) to supply …
FDA approves Janssen’s Xarelto for blood clot prevention
October 15, 2019Manufacturing and Production, Sales and Marketing FDA, Janssen, US, Xarelto, pharma, thromboembolism
Janssen’s Xarelto (rivaroxaban) has secured FDA approval for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalised acutely …
FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer
September 19, 2019Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer
Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
Janssen chalks up two more indications in Europe for Imbruvica combo therapies
August 14, 2019Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma
Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …
Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40%
August 1, 2019Sales and Marketing Alligator Bioscience, Janssen, pahrma
Janssen has decided to hand back the rights to an experimental CD40 agonistic antibody to Alligator Bioscience as it reassesses …
Janssen secures two positive CHMP opinions for Imbruvica label expansions
July 1, 2019Sales and Marketing CHMP, EMA, Europe, Janssen, imbruvica, pharma
Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human …
Janssen’s Darzalex combo approved by FDA in transplant-ineligible multiple myeloma patients
June 28, 2019Medical Communications, Sales and Marketing Janssen, darzalex, mutiple myeloma, pharma
Janssen’s Darzalex (daratumumab) has secured FDA approval in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple …
Top Ten most popular articles on Pharmafile.com this week!
June 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer
It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …
Darzalex combo makes strong Phase 3 showing in multiple myeloma
June 4, 2019Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma
Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …
Janssen’s Imbruvica shows superiority in Phase 3 trials
June 4, 2019Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial
Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …
Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer
June 3, 2019Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer
Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …
Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup
May 30, 2019Research and Development Janssen, darzalex, pharma
Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …
Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression
May 23, 2019Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression
Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …
Top Ten most popular articles on Pharmafile.com this week!
May 17, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics
Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
